Meet Arpeggio Biosciences

Ardeshir received his PhD from UNC Chapel Hill where he studied molecular dynamics of diseased proteins. He went on to do his postdoctoral fellowship at AstraZeneca and then worked as an investigator at Novartis. Ardeshir leads Arpeggio's computational chemistry efforts, bridging the gap between AI, biology, and medicinal chemistry.

Carter received his BA from the University of Southern Maine where he studied general biology. He went on to investigate novel synthetic lethality relationships in DNA damage and repair pathways with the D’Andrea Laboratory at the Dana Farber Cancer Institute. At Arpeggio, Carter focuses on drug screening and model development.

Dave has over 20 years of experience running and managing molecular biology labs at Harvard Medical School, Martek Biosciences, and the University of Colorado. At Arpeggio, Dave connects lab operations to our drug discovery initiatives.

Jeff received his BS in Bioengineering - Cell & Tissue Engineering from UC Berkeley College of Engineering. Jeff brings an extensive background of leading development teams responsible for deploying and maintaining integrated systems. At Arpeggio, he manages method development and support of our platform and R&D pipelines.

Jenna received her PhD from the University of Colorado where she focused on the mechanisms of RNA Pol II mediated transcription and collaborated with Syros Pharmaceuticals on a novel CDK7 inhibitor. At Arpeggio, Jenna focuses on target discovery and validation for transcriptional addiction mechanisms in cancer.

Joey received his PhD in Computer Science from the University of Colorado where he focused on the intersection of AI and cancer genomics. From this, Joey developed the founding IP for Arpeggio. After training at Merck and Forma Therapeutics, Joey founded Arpeggio with Laura and Tim. He was awarded Forbes 30-under-30 in 2020.

Kevin has over 25 years of corporate development experience across established biotechnology companies, such as Agouron Pharmaceuticals and Gilead, and venture-backed start-ups, notably, Achillion Pharmaceuticals, Ambrx Biopharma and Plexium. Kevin’s transactional experience includes platform and asset-based collaboration and license agreements as well as mergers and acquisitions.

Laura received her BA in Psychology at the University of Nebraska. She went on to found and operate multiple companies while advising startups on rapid growth potential as a business operations consultant. Laura founded Arpeggio alongside Joey and Tim where she leads operations, financial management, and legal teams.

Leah received her PhD in Biochemistry from the University of Colorado where she used microscopy and genomics to study the role of zinc in transcriptional regulation. Prior to grad school, Leah worked at MA General Hospital where she screened cancer cell lines to identify novel therapeutics. At Arpeggio, Leah focuses on scaling and automating drug screening efforts.

Reo received his MA in Bioengineering from UC San Diego where he studied systems biology. Reo came to us from a drug discovery start-up and at Arpeggio, he works at the interface of drug screening, automations, and assay development.

Richard received his PhD from the University of East Anglia (UK) where he studied disrupting protein-protein interactions. Richard previously worked on targets for oncology and rare diseases. At Arpeggio, Richard works on advancing hit compounds to leads for drug discovery.

Tim received his PhD in Molecular Biology from the University of Colorado where he focused on mechanisms or eukaryotic transcription. After doing his postdoctoral fellowship at Harvard Med, Tim founded Arpeggio alongside Joey and Laura. Tim leads Arpeggio's transcriptomic drug screening efforts.